Ignite Creation Date:
2024-10-25 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06601127
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-02
Brief Title:
Study of Tiprogrel in the Treatment of High-risk Patients With Acute Ischemic Cerebrovascular Events
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2 Randomised Double-blind Positive-controlled Multicentre Study of Tiprogrel in the Treatment of Patients With Acute Minor Ischaemic Stroke or High-risk Transient Ischaemic Attack
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to evaluate efficacy and safety of Tiprogrel in the treatment of patients with acute ischemic cerebrovascular events
Detailed Description:
To evaluate the safety and efficacy of Tiprogrel at different doses compared with cloppidogrel in the treatment of Patients with Acute Minor Ischaemic Stroke or High-risk Transient Ischaemic Attack
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None